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PharmacokineticsAbstract Ginseng fruit saponins (GFS) extracted from the ginseng fruit are the bioactive triter-
penoid saponin components. The aim of the present study was to develop a drug delivery system
called proliposome using sodium deoxycholate (NaDC) as a bile salt to improve the oral bioavail-
ability of GFS in rats. The liposomes of GFS were prepared by a conventional ethanol injection and
formed the solid proliposomes (P-GFS) using spray drying method on mannitol carriers. The for-
mulation of P-GFS was optimized using the response surface methodology. The physicochemical
properties of liposome suspensions including encapsulation efﬁciency, in vitro drug release studies,
particle size of the reconstituted liposome were tested. The solid state characterization studies using
the method of Field emission-scanning electron microscope (FE-SEM), Fourier transform infrared
(FT-IR) and Differential scanning colorimetric (DSC) were tested to study the molecular state of P-
GFS and to indicate the interactions among the formulation ingredients. In vitro studies showed a
delayed release of ginsenoside Re (GRe). In vivo studies were carried out in rats. The concentrations
of GRe in plasma of rats and its pharmacokinetic behaviors after oral administration of GFS, Zhe-
nyuan tablets (commercial dosage form of GFS) and P-GFS were studied using ultra performance
liquid chromatography tandem mass spectrometry. It was founded that the GRe concentration time
curves of GFS, Zhenyuan tablets and P-GFS were much more different in rats. Pharmacokinetic
behaviors of P-GFS showed a second absorption peak on the concentration time curve. The
S114 F. Hao et al.pharmacokinetic parameters of GFS, Zhenyuan tablets, P-GFS in rats were separately listed as fol-
lows: T max 0.25 h, C max 474.96 ± 66.06 ng/ml and AUC01 733.32 ± 113.82 ng/ml h for GFS;
T max 0.31 ± 0.043 h, C max 533.94 ± 106.54 ng/ml and AUC01 1151.38 ± 198.29 ng/ml h for
Zhenyuan tablets; T max 0.5 h, C max 680.62 ± 138.051 ng/ml and AUC01 2082.49 ± 408.33
ng/ml h for the P-GFS. The bioavailability of P-GFS was nearly 284% and 181% of the GFS
and Zhengyuan tablets respectively. In conclusion, the proliposomes signiﬁcantly enhanced the
drug bioavailability, absorption in the gastrointestinal tract and decreased its elimination time of
GRe in rats and could be selectively applied for oral delivery of GFS.
 2015 TheAuthors. Production and hosting by Elsevier B.V. on behalf ofKing SaudUniversity. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Ginseng (panax ginseng) is a highly used and valued Chinese
herbal medicine to treat a variety of ailments for thousands
of years. Saponins extracted from the ginseng plant are the
active compounds and responsible for most of the pharmaco-
logical effects of ginseng. Ginseng fruit saponins (GFS)
extracted from the berry of Ginseng possess higher ginsenoside
contents than the roots and recently are a hotspot in treating
many diseases (Yang et al., 2010). GFS are a group of the
dammarane-type triterpene saponins. In previous publications,
it had been proved that GFS showed a positive bioactivity
effect in atherosclerosis, anti-diabetic and anti-obesity effects,
diabetes associated cognitive deﬁcits, anti-inﬂammatory activ-
ity, histamine and cytokine release, anti-stress effect, and sys-
temic lupus erythematosus (Attele et al., 2002; Huo, 1984;
Park et al., 2012; Yang and Zhang, 1986; Zhang and Jiang,
1981; Zhang et al., 1984). Ginsenoside Re (GRe) which con-
tains the structural backbone of protopanaxatriol is the most
important major bioactivity constituents of GFS and has been
chosen as the character for evaluation of GFS (Lee et al.,
2014). In particular, a previous study showed that ginsenoside
Re in ginseng berry extracts showed a superior oral absorption
of ginsenoside Re at equivalent ginsenoside Re dose to pure
ginsenoside Re, indicating that GFS might be a good form
for ginsenoside Re intake (Joo et al., 2010).
GFS is well-known as the BCS III (Biopharmaceutics Clas-
siﬁcation system) drugs with high solubility and low perme-
ability. The poor oral bioavailability was observed for its
low permeability and fast degradation and clearance in the
gastrointestinal tract (Kim et al., 2013; Peng et al., 2012). To
improve bioavailability of GFS, a variety of formulations such
as nano particle, phospholipid complex, liposome have been
used in previous studies (Ajazuddin and Saraf, 2010). Phos-
pholipids have the characteristics of excellent biocompatibility
and amphiphilicity. These unique properties make phospho-
lipids most appropriate to be employed as important pharma-
ceutical excipients (Li et al., 2015). And the lipid-based drug
delivery systems enhance the intestinal drug permeability and
solubility (Larsen et al., 2011; Porter et al., 2008; Trevaskis
et al., 2008). Liposomes can entrap both hydrophilic and
hydrophobic agents, which could protect the entrapped agents
from external destructive conditions, such as light, pH and
enzymes (Chen, 2008).In addition to the property of liposome
adhesion to and absorption into the intestinal epithelial cells,
liposome as a novel method was used to improve the bioavail-
ability of GFS. Considering the poor physicochemical stability
problems of liposome including aggregation, fusion, oxidationand active agent’s leakage, one effective approach is used to
formulate the aqueous liposome into solid proliposome
deﬁned as dry, free-ﬂowing particles, containing water soluble
carrier particles coated with phospholipids (Yanamandra
et al., 2014). Once contacted with water, proliposome could
immediately form a liposomal dispersion and be more uniform
in size. The methods of preparing proliposome include single
step spray drying method (Patil-Gadhe and Pokharkar,
2014), vacuum evaporation (Janga et al., 2012; Keon-
Hyoung Song and Chang-Koo Shim, 2002), ﬁlm deposition
method (Janga et al., 2012), and ﬂuidized bed method (Chen
and Alli, 1987). The Spray drying method was used in this
study considering the application in industries. Some studies
focusing on proliposome surface charge and Carboxymethyl
chitosan coated modiﬁcation were reported to further improve
the absorption of liposomes in the gastrointestinal tract (Bai
et al., 2011; Janga et al., 2012). A liposome containing bile salts
called bilosomes is widely studied and is a hotspot to biocom-
patibility compared with surface charge (Senior, 2001). Bilo-
somes have been applied to the oral immunization of peptide
and protein antigens (Conacher et al., 2001) and could
improve the integrity and stability of oral liposomes in gas-
trointestinal media (Hu et al., 2013). The enhanced oral
absorption of bilosomes could be achieved by improving
in vivo residence time, and permeation across the bio-
membranes and trans-endocytosis internalization has been
reported in a previous study (Niu et al., 2014). Sodium deoxy-
cholate (NaDC) had been used as a bile salt to improve
absorption and stability of vesical particles for the drug appli-
cation dosages in oral delivery system (Gangadhar et al.,
2014).
In the present study, the P-GFS containing sodium deoxy-
cholate was ﬁrstly prepared and optimized to improve the oral
bioavailability of the GFS. The physicochemical properties
and the molecule state of the proliposomes were characterized
by methods of FE-SEM, DSC and FT-IR. Particle size, encap-
sulation efﬁciency, stability evaluation, in vitro drug release
and in vivo bioavailability studies in rats of P-GFS were also
investigated to evaluate in this delivery system.
2. Materials and methods
2.1. Materials
Ginseng fruit saponins (GFS) were gifted from Bo Xiang Phar-
maceutical Group (Ji Lin, China). Egg yolk phosphatidyl-
choline (EPC) with the purity over 80%, was purchased
from the Guangzhou hanfang modern Chinese medicine
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99.9%), acetonitrile (HPLC-grade), methanol (HPLC-grade),
ethyl acetate, isopropanol, and phosphoric acid
(HPLC-grade) were obtained from Sigma–Aldrich Co. (MO,
USA). Sodium deoxycholate (NaDC), mannitol, anhydrous
ethanol, hydrochloric acid, and other chemical reagents of
analytical grade or better were obtained from Sinopharm
Chemical Reagent Co. (Shanghai, China). The reference stan-
dards of ginsenoside Re, Salidroside (IS) were purchased from
the National Institute for Food and Drug Control of China.
2.2. Preparation of P-GFS
The spray drying method was used in this study for the prepa-
ration of proliposomes. Brieﬂy, egg yolk phosphatidylcholine
(EPC) was dissolved in anhydrous ethanol to obtain lipid solu-
tion. GFS were added in water and heated to a temperature of
55 C to obtain a transparent drug solution. The lipid and
sodium deoxycholate (NaDC) solution was injected quickly
into drug solution under stirring (600 r/min) for 10 min at
55 C to obtain a liposome suspension containing NaDC. As
the temperature was at 37 C, manntiol was added to the sus-
pension with stirring for 5 min in order to mix homogeneity
completely before the spray drying. The spray dying relative
parameters were set as follows: The inlet temperature was
130 C and a feed rate was 400 ml/h.
2.3. Optimization of proliposomes
The single-factor tests were ﬁrst carried out to ascertain the
factors of the preparation methods of proliposomes. And then
the main factors affecting the particle size and encapsulation
efﬁciency (EE) of P-GFS were conﬁrmed. Based on the result
of single-factor tests, three factors which affected most namely
the concentration of EPC (X1), the ratio of EPC and manntiol
(X2), and the ratio of EPC and NaDC (X3) were selected to fur-
ther optimize the composition of GFS proliposome (the ratio
of drug and EPC concentration was 1:1). The selected factors
were subjected to analysis by response surface methodology
(RSM) with a three factor-three coded level Box-Behnken
design (BBD). The range and the levels of experimental vari-
ables investigated in this study are presented in Table 1. In
addition, several tests were done to validate the experiment
design according to the optimal composition. Response sur-
faces describing the relationship between each factor and index
were drawn according to the ﬁtting equation. Finally, the opti-
mized formula from the response surface drawing was applied
to produce P-GFS and execute predictive analysis.Table 1 Coded and levels of the variables used in
Box-Behnken design.
Factors Code Range and levels
1 0 1
EPC concentration (mg/ml) X1 1 2 3
mannitol:EPC X2 3:2 5:2 7:2
NaDC:EPC X3 1:8 1:4 1:2
The volume of the dissolution system was ﬁxed at 400 ml.2.4. HPLC analysis of ginsenoside Re
The quantitative ginsenoside Re analysis was performed using
an HPLC System (SPD-10AVP HPLC, Shimadzu, Tokyo,
Japan) with a ultraviolet detector. The separation and quanti-
tation of ginsenoside Re were achieved using an HC-C18 col-
umn (150 mm  2.8 mm, 3 lm; Agilent Corporation, Santa
Clara, CA) with a mobile phase ﬂow rate of 1.0 ml/min and
a wavelength of 203 nm at 30 C. The mobile phase consisted
of water containing 0.04% (v/v) phosphoric acid and acetoni-
trile. The injection volume was 20 ll and the determination of
ginsenoside Re was completed in 15 min and the peak time of
ginsenoside Re was in 7.8 min. Excellent linearity was achieved
with correlation coefﬁcients greater than 0.999 for ginsenoside
Re within the range of 0.5–100 lg/ml.
2.5. Assay and determination of entrapment efficiency
To access the concentration of ginsenoside Re encapsulated
into the liposomes, the activated dialysis bags which were
placed onto measurement beakers were used to separate the
encapsulated and free ginsenoside Re. The liposome suspen-
sions were prepared by adding water into proliposome powder
of GFS and were placed into the dialysis bag for 12 h. An ali-
quot of 5 ml dissolution from the beaker was withdrawn and
the amount of free ginsenoside Re (A) was measured by the
HPLC method. The total amount of ginsenoside Re (I) was
determined by adding methanol into the GFS. The amount
of encapsulated GRe was got by the total amount of gin-
senoside Re minusing the amount of free ginsenoside Re. The
encapsulation efﬁciency (%) was calculated using the following
equation:
The encapsulation efficiency of ginsenoside Re ð%Þ
¼ ðI A=IÞ  100
To conﬁrm the feasibility and accuracy of the method, an
aliquot of 5 ml dissolution from the dialysis bag after 12 h
was taken out for the HPLC determination as the ginsenoside
Re encapsulated (B). The recovery of ginsenoside Re was
obtained by calculating the ratio of experiment total amount
(I= A+ B) with the true usage (M) added in the test.
The recovery of ginsenoside Re ð%Þ ¼ I=M 1002.6. Measurement of particle size and zeta potential of the
reconstituted liposome
The proliposome powders were hydrated with distilled water
and agitated manually for 5 min and then the resultant lipo-
some dispersion was used for the determination of particle size
and zeta potential using a Nano particle and ZETA poten-
tiometer (NANO ZS90, Malvern, US).
2.7. Solid state characterization
2.7.1. Field emission-scanning electron microscope (FE-SEM)
The surface morphology of mannitol, the pure drug, and pro-
liposome powders was investigated by Field emission scanning
electron microscope (FE-SEM) (JSM-6700F, JEOL, Japan).
The Samples contacted with distilled water were ﬁrst added
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ples were ﬁxed on a brass stub using double-sided adhesive
tape and obtained electric conduction by coating with a thin
layer of gold. SEM images were recorded at 3.0 kV accelerat-
ing voltage.
2.7.2. Differential scanning colorimetry (DSC)
TheDSCmethodwas performed to evaluate themolecular state
of the drug in the proliposome formulation by theMETTLER
DSC STARe System. (Mettler-Toledo, Germany). GFS, EPC,
mannitol, NaDC, physical mixture and proliposomes with pre-
cise weight were placed ﬂatly in aluminum crucibles
(!5.4mm  2.0mm) for Thermal analysis and heated at a tem-
perature range of 25–300 C under a constant nitrogen gas ﬂow
of 150 ml /min with a heating rate of 10 Cperminute. A second
blank aluminum crucible was sealed as the reference control.
2.7.3. Fourier transform infrared (FT-IR) spectroscopy
Infrared spectra were recorded by a FT-IR spectrophotometer
(IR Prestige-21, SHIMADZU, Japan) for the analysis of an
interaction effect between the GFS and mannitol. The trans-
parent tablets of samples including GFS, EPC, NaDC, manni-
tol, physical mixture and the P-GFS were obtained by a
conventional KBr pellet method. The KBr tablet spectrum
was ﬁrst collected under identical conditions as the back-
ground. Each spectrum was derived from 10 single averaged
scans in the region of 400–4000 cm1 at a spectral resolution
of 4 cm1.
2.8. In vitro release study
In vitro release study of P-GFS was performed using a dialysis
bag (MW cut off 8000–12000). The dispersions of GFS and P-
GFS containing equal amounts of GFS were placed into the
dialysis bags immersing in 500 ml medium (pH = 1.2 HCl,
pH = 6.8 phosphate buffer saline). The medium was stirred
continuously at 300 rpm and kept at the temperature of 37
± 0.5 C. At different time intervals, an aliquot volume
(1 ml) of dissolution was withdrawn and the same volume of
fresh release medium was added into the measurement beakers
to maintain constant volume. The samples were ﬁltrated using
a 0.45 lm cellulose nitrate membrane and then injected to the
HPLC for analysis. The wavelength was ﬁxed at 203 nm.
2.9. Oral bioavailability study
2.9.1. Animals
Male Wistar rats (n= 18, 260 ± 20 g) were purchased from
the Laboratory Animal Center of Jilin University (Changchun,
China). All the rats were housed at a temperature of 25
± 2 C, 12 h light/dark cycle with free access to water and
food for 1 week before the experiment. The experimental pro-
tocol was approved by the Laboratory Animal Center of Jilin
University (license No. SCXK-(JI) 2011-0003). Before drug
administration, the rats were fasted over 12 h and had free
access to water.
2.9.2. Pharmacokinetic study
The commercially available drug of GFS called Zhengyuan
tablets was used to be the positive control compared withcrude GFS and P-GFS. Eighteen rats were randomly divided
into 3 groups. 3 ml of the distilled water was added into proli-
posomes, GFS and Zhenyuan tablets crushed and the suspen-
sions were stirred for 5 min using a vortex. One group was
given oral administration of GFS at a dose of 300 mg/kg
and other groups were given the same way at a dose equivalent
to 300 mg/kg of GFS. Approximately 0.5 ml blood samples
obtained from the orbit were collected into heparinized cen-
trifuge tubes at 0.083, 0.167, 0.333, 0.5, 1, 2, 4, 6, 8, 10, 12
and 24 h post-dose, and were immediately centrifuged at
10,000 rpm for 10 min. Plasma samples were withdrawn and
stored at 20 C until UPLC-MS/MS analysis.
2.9.3. Assay method
2.9.3.1. UPLC-MS/MS analysis of ginsenoside Re in plasma. A
Waters Acquity UPLC system (Waters, Milford, MA, USA)
coupled to a Waters Xevo TQ-S triple quadruple mass spec-
trometry with an electrospray ion source and Mass Lynx soft-
ware version 4.1 (Waters, Milford, MA, USA) which was
called Ultra performance liquid chromatography–tandem mass
spectrometry (UPLC-MS/MS) was used to quantify ginsenoside
Re in rat plasma samples within 5 min. Separation of prepared
samples was achieved using aWaters Acquity UPLC BEH C18
column (2.1 mm  50 mm, 1.7 lm)with a 0.2-mmﬁlter (Waters,
Milford, MA, USA) maintaining at 40 C. The mobile phase
consisted of acetonitrile (A) and water (B) at 0.4 ml/min. The
gradient program is described as follows: 0–2 min, 5–70% A;
2–2.5 min, 70–5% A; 2.5–4.5 min, 5% A. The mass spectrome-
try was operated in the positive electrospray ionization (ESI+)
mode. Salidroside was chosen as the internal standard. The gin-
senoside Re and Salidroside were quantiﬁed independently at a
m/z 945.5? 637.5 (parent 945.5 and daughters 637.5) for gin-
senoside Re and a m/z 299.1? 119.0 (parent 299.1 and daugh-
ters 119.0) for salidroside. The voltages of the capillary and
source were 2.8 kV and 60 V. The temperature of the source
and desolvation were 150 C and 500 C, respectively. The gas
ﬂow of the cone and desolvation were 150 L/h and 1000 L/h,
respectively. The cone voltages for ginsenoside Re and
Salidroside were 50 V and 32 V respectively. The collision
energy for ginsenoside Re and Salidroside were 38 eV and
13 eV respectively.
2.9.3.2. Sample preparation. 100ul rat plasma samples were
spiked with 100ul internal standard solutions (25 ng/ml Sali-
droside) and 100 ll of 4 mmol hydrochloric acid and then vor-
texed for 10 s. The hydrolyzation by adding hydrochloric acid
lasted for 30 min at 80 C in a water bath. 700 ll volume of
ethyl acetate and n-butyl alcohol mixtures (1:1) was added into
the mixture samples. After vortexing for 1 min and centrifuga-
tion at 12,000 rpm for 10 min, the supernatant organic solu-
tion was dried at 37 C under a low speed of nitrogen
stream. The residues were reconstituted by adding 100 ll of
acetonitrile and 1 ll of the prepared samples were injected into
the UPLC-MS/MS system for analysis.
2.10. Data analysis
For the pharmacokinetic study, the pharmacokinetic parame-
ters of the maximum plasma concentration (Cmax), the time of
the maximum concentrations (Tmax), the elimination half-time
(T1/2), the area under concentration–time curve (AUC01),
Oral availability of ginseng fruit saponins S117and the elimination rate (Cl_F_obs) for GFS, Zhenyuan tablets
and P-GFS were calculated through non-compartmental
model analysis using the Drug and Statistics 3.0 program
(DAS, life science college of Jilin university, Changchun,
China). All the data were expressed as mean ± standard devia-
tion (S.D.). The identiﬁcation of signiﬁcances between different
groups was carried out with t-test. A p value< 0.05 was con-
sidered statistically signiﬁcant.
2.11. Stability studies
The formulations stored at room temperature and in refriger-
ator (4 ± 2 C) for a period of 90 days were formulated to
study the stability of P-GFS. At deﬁnite time intervals (0, 10,
30, 60, and 90 days) samples were withdrawn and hydrated
with distilled water to evaluate vesicle size and encapsulation
efﬁciency and physical appearance of the P-GFS.
3. Results and discussion
3.1. Preparation of GFS proliposomes
The P-GFS were prepared successfully as described previously.
Spray drying technology was chosen for preparation of P-GFSEE ¼ 62:4 3:0875  X1  3:375  X2  3:9875  X3  11:95  X1  X1  0:725  X1  X2
7:35  X1  X3  13:525  X2  X2  5:875  X2  X3  9:3  X3  X3
Table 2 Response surface central composite design and
experimental encapsulation efﬁciency EE (%).
No. Levels of independent factors Response EE (%)
X1 X2 X3
1 1 3:2 1:4 42.4
2 1 7:2 1:4 40.1
3 3 3:2 1:4 35.2
4 3 7:2 1:4 30.0
5 2 3:2 1:8 42.2
6 2 3:2 1:2 46.7
7 2 7:2 1:8 44.2
8 2 7:2 1:2 25.2
9 1 5:2 1:8 40.0
10 3 5:2 1:8 51.0
11 1 5:2 1:2 46.0
12 3 5:2 1:2 27.6
13 2 5:2 1:4 62.4
14 2 5:2 1:4 63.6
15 2 5:2 1:4 61.2considering the further application to the pharmaceutical
industry. The preparation conditions were optimized ﬁrstly
using the single-factor tests. Anhydrous ethanol was chosen
as the solvent to dissolve EPC and NaDC for its low toxicity,
high dissolubility and the most important character that it’s
easy to clear away. A previous study reported that ethanol
could make the lipid distribution more uniform and efﬁcient
(Xu et al., 2009a). As the process of spray drying tends to
destroy the membrane function of the phospholipid bilayer
and causes a pronounced decrease in the encapsulation efﬁ-
ciency. It has been reported that mannitol, sorbitol and lactose
are commonly used as drug carriers (Janga et al., 2012; Patil-
Gadhe and Pokharkar, 2014; Xu et al., 2009b). The P-GFS
had a viscous appearance and poor ﬂuidity when sorbitol
and lactose were used as the carriers in the preliminary exper-
iment. Mannitol was widely used as dry powder carriers and it
can overcome the drawbacks of sorbitol and lactose and
ensure the quality of liposomes during production process
and storage due to its homogeneous surface properties
(Littringer et al., 2012). Mannitol carrier particles offer similar
adhesion conditions to active particles attached to the surface.
So mannitol was chosen as the carrier for its properties of high
water dissolution and ﬂuidity in preparing proliposomes
powder.
Before the addition of carriers and spray drying, the forma-
tion of a liposome suspension was completed ﬁrst. Instead of
the classical cholesterol, sodium deoxycholate (NaDC) was
selected as the bile salt surfactant to improve stability, perme-
ability and bioavailability for the liposome in the gastrointesti-
nal tract (Gangadhar et al., 2014). Incorporation of bile salt inliposomal formulation could stabilize the membrane against
the detrimental effects of bile acids in the gastrointestinal tract
and have better permeability characteristics for liposomes (Niu
et al., 2014).
The injected temperature was ﬁxed at 55 C, higher than the
phase transition temperature of EPC because the higher tem-
perature could facilitate higher solubility and dispersibility of
GFS in ethanol/water so as to form GFS more
homogeneously.
3.2. Optimization of proliposomes and statistical analysis
There were 15 experimental runs for optimizing the three indi-
vidual parameters in the Box-Behnken design (BBD) and the
composition and entrapment efﬁciency (EE) of GRe according
to the factorial design is shown in Table 2. The results showed
that the EE ranged from 25.2% to 63.6%. The maximum EE
value was found in conditions of X1 = 1.92123 mg/ml,
X2 = 12:5 and X3 = 23:100. The values of regression coefﬁ-
cients were calculated, the response variable and the test vari-
ables were related by the following second-order polynomial
equation:The statistical signiﬁcance of the regression model was checked
by F-test and p value, and the analysis of variance (ANOVA)
for the response surface quadratic model is shown in Table 3,
in which the small p value for the model implied the model was
statistically signiﬁcant. The p value for the ‘lack of fit’ test was
0.12368, indicating the quadratic model was adequate. In
Table 3, the interaction coefﬁcients (X1X3, X2X3) were found
to be signiﬁcant (p< 0.01). The determination coefﬁcient
Table 3 Estimated regression model of relationship between response variables (EE) and independent variables (X1, X2, X3).
Source df Sum of squares Mean square F value P-value Prob > F
Model 9 1977.235 219.6928 32.13527 0.000672 Signiﬁcant
X1 1 76.26125 76.26125 11.15501 0.020554
X2 1 91.125 91.125 13.32919 0.014734
X3 1 127.2013 127.2013 18.60619 0.007617
X1X2 1 527.2708 527.2708 77.12583 0.000318
X1X3 1 2.1025 2.1025 0.30754 0.603084
X2X3 1 216.09 86.40 31.60828 0.002465
X1
2 1 675.4177 675.4177 98.79583 0.000176
X2
2 1 138.0625 138.0625 20.19491 0.006436
X3
2 1 319.3477 319.3477 46.71216 0.001023
Residual 5 34.1825 6.8365
Lack of ﬁt 3 31.3025 10.43417 7.245949 0.12368 Not signiﬁcant
Pure error 2 2.88 1.44
Cor. total 14 2011.417
R2 = 0.9830, R2Adj = 0.9524, R
2
Pred = 0.9524.
Figure 1 Response surface plot showing the effect of (A) concentration of EPC, (B) ratio of mannitol to EPC, and (C) ratio of NaDC to
EPC.
S118 F. Hao et al.(R2 = 0.9830) revealed that the experimental results ade-
quately ﬁtted the equation selected (Ashraf et al., 2013a).
To better understand the predictive models of the results,
three-dimensional graphs of the models, the response surfacediagrams of the EE of GFS proliposomes are shown in
Fig. 1. With an increase in the concentration of EPC, the ratio
of mannitol to EPC and NaDC to EPC, the EE of GFS
proliposomes ascended at ﬁrst and descended later. It may
Figure 2 Size distribution (A) and (B) zeta potential distribution of the reconstituted liposomes.
Figure 3 Field emission-scanning electron microscope (FE-SEM) images of (A) mannitol, (B) GFS, (C) the reconstituted liposomes of
P-GFS at 10,000 magniﬁcation.
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to the EE was less than to EPC and NaDC. The amount of
NaDC also had an effect on the EE. From Fig. 1B and C, it
may be seen that if the amount of NaDC was too high, the
EE decreased. A reason for this result may be that the further
increased amount of bile salt into liposomal lipid bilayers
destroyed the vesicular structure (Andrieux et al., 2009).
The suitability of the model equation for predicting the
optimum response values was tested using the recommended
optimum conditions. The set of optimum composition, deter-
mined using the RSM optimization approach, was tested
experimentally according to the model equation (GFS and
EPC 2 mg/ml, mannitol: EPC = 12:5, NaDC: EPC =
23:100). Three batches of proliposomes were prepared accord-
ing to the optimized composition and EEs of each batch were
determined. The mean experimental EE was 62.37 ± 0.67 %
(n= 3).
3.3. Measurement of particle size and zeta potential of the
reconstituted liposomes
The particle size of the reconstituted liposomes showed a size
range of 275.4 ± 10.74 nm (Fig. 2A) for the spherical particles
which was further conﬁrmed by FE-SEM (Fig. 3C). The zeta
potential value was 28.6 ± 4.77 mV (Fig. 2B).Figure 4 DSC thermograms of (A) GFS, (B) EPC, (C) Na3.4. Solid state characterization
3.4.1. Field emission-scanning electron microscope (FE-SEM)
The surface morphology of mannitol, GFS and reconstituted
liposomes were investigated by FE-SEM, and the images are
represented in Fig. 3. The reconstituted solution prepared by
adding distilled water into the powder of mannitol, GFS and
P-GFS were all dried naturally on the silicon wafer. The typi-
cal crystalline structure of mannitol at 700 magniﬁcation was
obviously different from the surface of GFS and reconstituted
liposomes. The hollow ﬁber structure (as the bold arrow
marked) of mannitol powders (Fig. 3A) observed in the scan-
ning electron microscope indicated that the mannitol was a
better carrier and had no effect to the formation of reconsti-
tuted liposomes compared with Fig. 3B and C. GFS were
encapsulated into the spherical lipid particles with a character-
istic rough surface as the bold arrow marked in Fig. 3C com-
pared with Fig. 3B. The images of FE-SEM showed that the
GFS liposome could be successfully prepared by the prolipo-
some contacted with water.
3.4.2. Differential scanning colorimetry (DSC)
The molecular state of GFS in proliposome formulation was
evaluated by performing the DSC analysis of GFS, EPC,
NaDC, mannitol, physical mixture of GFS, EPC, NaDC,DC, (D) mannitol, (E) physical mixture and (F) P-GFS.
Figure 6 In vitro release proﬁles of the reconstituted liposomes
(P-GFS) and control drug solution (GFS) in artiﬁcial gastric ﬂuid
Oral availability of ginseng fruit saponins S121and mannitol, and proliposomes in Fig. 4. As is shown in
Fig. 4A, GFS had an endothermal peak with a wide range
because it is a mixture of compounds. It had an obvious peak
value at 71.08 C so the character DSC value of GFS was set at
71.08 C. The DSC thermogram of EPC exhibited a peak value
at 148.96 C (Fig. 4B) .The formation of this peak might be
due to the phase transition from gel-like state to liquid–crystal
state (Singh et al., 2014). The DSC thermogram of mannitol
showed an endothermal peak at 167.11 C and the NaDC
showed an outstanding endothermal peak at 161.84 C respec-
tively within the temperature range from 25 C to 250 C. The
physical mixture showed an endothermal peak at 167.16 C.
Compared with the mannitol (the most important major com-
ponent) peak (Fig. 4D), nearly no obvious change was found
in the physical mixture (Fig. 4E). The endothermal peaks for
the other ingredients were so small compared with mannitol
that the thermogram only showed the peak of mannitol.
What’s more, mannitol took the maximum weight of the phys-
ical mixture. Different from the physical mixture, the DSC
thermogram of P-GFS (Fig. 4F) had a endothermal peak at
164.36 C, a big peak move compared with the mannitol peak.
These results possibly indicated that components in prolipo-
somes had some interaction during proliposome formation
resulting in mannitol peak migration, as previous researchers
have suggested (Tan et al., 2012). It also could be speculated
that there was no interaction among the excipients in the
physical mixture (Ashraf et al., 2013b).Figure 5 FT-IR spectra of (A) GFS, (B) mannitol, (C) N3.4.3. Fourier transform infrared (FT-IR) spectroscopy
The FT-IR spectra of GFS, mannitol, NaDC, EPC, physical
mixture and P-GFS are shown in Fig. 5. The characteristic
absorption peaks of GFS, mannitol, NaDC, EPC, physicalaDC, (D) EPC, (E) phyiscal mixture and (F) P-GFS.
(pH 1.2) and intestinal ﬂuid (pH 6.8) (mean ± SD, n= 3).
S122 F. Hao et al.mixture and proliposomes were as follows: 2360 cm1, 1653 and
1558 cm1 for GFS (Fig. 5A); 1417 cm1, 1080 cm1and
1018 cm1 for mannitol (Fig. 5B); 1558 cm1 and 1400 cm1for
NaDC (Fig. 5C); 1558 cm1 and 1539 cm1for EPC (Fig. 5D).
The characteristic absorption peaks of all the ingredients could
be seen in the physical mixture (Fig. 5E) indicating nomolecular
interaction effect among the ingredients. However, in the FT-IR
spectra of proliposomes (Fig. 5F), the characteristic absorption
peaks seen in the other samples were absent or shielded and new
peaks at 1734 cm1 and 1456 cm1 were seen in the FT-IR spec-
tra compared with physical mixture. The results indicated that
some weak molecular interactions among proliposome ingredi-
ents had occurred in the preparation process of proliposomes. In
the spectra of proliposomes, the characteristic absorption peaks
of mannitol were still existing because the amount of mannitol
was higher than the other ingredients in proliposomes.
3.5. In vitro release study
In vitro release proﬁles of GRe from the reconstituted lipo-
somes solution of P-GFS and GFS solution in artiﬁcial gastric
ﬂuid (pH 1.2) and artiﬁcial intestinal ﬂuid (pH 6.8) are shown
in Fig. 6. Compared with control drug solution, GRe in the
liposome solution had a sustained release at pH 6.8 while
GRe in reconstituted liposomes and GFS solution had a low
release at pH 1.2. In 12 h, only 10% of the GRe for GFS
and P-GFS in pH = 1.2 was released compared with nearly
95% of G-Re for GFS and 70% for P-GFS in pH = 6.8.Figure 7 A and B represents separately mean GRe concentration–tim
GFS, Zhenyuan tablets and P-GFS respectively (mean ± SD, n= 6).
Table 4 Pharmacokinetics parameters of G-Re for GFS, Zhen
respectively (mean ± SD, n= 6).
Formulations Cmax (ng/ml) Tmax (h)
GFS 474.96 ± 66.06 0.25 ± 0.00
Zhenyuan tablets 533.94 ± 106.54 0.31 ± 0.043
P-GFS 680.62 ± 138.051# 0.5 ± 0.00*
*,#,$ Indicates signiﬁcant difference at p< 0.05, p< 0.01, and p< 0.001The results revealed that the pH and release medium had an
effect on the release of GRe from liposomes. It could be spec-
ulated that the GRe was mainly absorbed in the intestinal
tract. The formation of micelle of the GFS and reconstituted
liposomes observed in pH = 1.2 may be contribution to the
lower release of GRe (Khaskheli et al., 2015).
3.6. Pharmacokinetic study
Pharmacokinetic study was carried out to compare the oral
bioavailability of GFS, Zhenyuan tablets and proliposomes
(P-GFS) by measuring the concentrations of GRe in rat
plasma after oral administration. The mean plasma concentra-
tion–time proﬁles of GFS, Zhenyuan tablets and P-GFS are
displayed in Fig. 7A and B. The main pharmacokinetic param-
eters of GFS, Zhenyuan tablets and proliposomes (P-GFS) are
shown in Table 4. It was founded that the mean plasma con-
centration versus time proﬁle of GFS, the commercial dosage
form of GFS (Zhenyuan tablets) and P-GFS suspensions were
much more different. Pharmacokinetic behaviors of P-GFS
showed a second absorption peak on the concentration versus
time proﬁle and had a high maximum concentration and resi-
dence time. The pharmacokinetic parameters of GFS, Zhe-
nyuan tablets and P-GFS in rats were respectively listed as
follows: Tmax 0.25 h, Cmax 474.96 ± 66.06 ng/ml and AUC01
733.32 ± 113.82 ng/ml h for GFS; Tmax 0.31 ± 0.043 h, Cmax
533.94 ± 106.54 ng/ml and AUC01 1151.38 ± 198.29
ng/ml h for Zhenyuan tablets; Tmax 0.5 h, Cmax 680.62e proﬁles for 24 h and 2 h in rat plasma after oral administration of
yuan tablets and proliposomes (P-GFS) formulations in rats
T1/2 (h) AUC0–1 (ng/ml/h) Cl_F_obs (ml/h)
7.72 ± 1.61 733.32 ± 113.82 2667.53 ± 395.50
10.15 ± 0.95 1151.38 ± 198.29 1760.44 ± 292.02
13.03 ± 1.30# 2082.49 ± 408.33$ 1043.87 ± 186.27$
, respectively.
Table 5 The stability of P-GFS in refrigerated temperature (4 ± 2 C).
Time (day) 0 10 30 60 90
Color Light yellow Light yellow Light yellow Light yellow Light yellow
GRe assaying(mg/ml) (x± s, n= 6) 1.9745 ± 0.02 1.9439 ± 0.25 1.9722 ± 0.07 1.9581 ± 0.16 1.9468 ± 0.34
Particle size analysis (nm) (x± s, n= 6) 278.1 ± 3.59 276.9 ± 5.23 273.9 ± 4.14 275.0 ± 1.09 276.6 ± 3.09
Encapsulation eﬃciency (%) (x± s, n= 6) 71 ± 2.54 69 ± 3.16 68 ± 4.58 68 ± 5.49 66 ± 3.91
Table 6 The stability of P-GFS in high temperature (37 ± 5 C).
Time(day) 0 10 30 60 90
Color Light yellow Light yellow Light yellow Light yellow Light yellow
GRe assaying(mg/ml) (x± s, n= 6) 1.9627 ± 0.12 1.9702 ± 0.09 1.9488 ± 0.34 1.9576 ± 0.41 1.9630 ± 0.09
Particle size analysis(nm) (x± s, n= 6) 279.6 ± 4.52 277.9 ± 3.98 275.3 ± 4.07 276.0 ± 2.43 277.1 ± 5.69
Encapsulation eﬃciency (%) (x± s, n= 6) 69 ± 3.16 67 ± 4.56 66 ± 2.37 65 ± 1.68 65 ± 4.01
Oral availability of ginseng fruit saponins S123± 138.051 ng/ml and AUC01 2082.49 ± 408.33 ng/ml h for
the P-GFS. The bioavailability of P-GFS was nearly 284%
and 181% of the GFS and Zhengyuan tablets respectively.
The values of Cmax, Tmax, T1/2, AUC0–1 and Cl_F_obs (ml/
h) for GRe in proliposomes showed obvious differences
(p < 0.05). The higher values of Cmax and AUC0–1 of GRe
in proliposomes compared with control and Zhenyuan tablets
obviously suggested that liposomes containing bile salt formu-
lation could improve the bioavailability of GRe. The possible
reasons for this are that liposomes containing sodium deoxy-
cholate by facilitating transition from liposomes to mixed
micelles could increase the stability and the permeability of
GRe in the intestinal tract and protect the GRe degradation
from enzyme as the previous study had showed (Porter
et al., 2008; Senior, 2001; Song et al., 2005). In addition, the
endocytosis by epithelial cells and the intestinal lymphatic
transport reduce the ﬁrst pass metabolism (Akbarzadeh
et al., 2013; Hu et al., 2013; Ju et al., 2013; Porter et al.,
2008). The double peaks’ curve of proliposome is also found
in Fig. 7A and B. The encapsulation efﬁciency of GRe was
about 63%, so the free GRe probably mainly contributed to
the ﬁrst peak. The second peak of the proliposome might also
be caused by the absorption of GRe encapsulated in liposomes
by the intestinal tract or the hepato-enteric circulation of GRe
and reabsorbed in the intestinal tract (Khan et al., 2015).3.7. Stability studies
The stability of the proliposome formulations was ascertained
by monitoring the physical appearance, particle size and
encapsulation efﬁciency after storage at room temperature
(37 C) and refrigerated temperature (4 C) for a period of
90 days. At deﬁned time intervals, the proliposomes were
reconstituted to form liposome dispersion. As shown in Table 5
and Table 6, no dramatic change was observed in the physical
appearance, particle size and encapsulation efﬁciency indicat-
ing the similar stability of the proliposome formulation stored
at room temperature compared with the refrigerated tempera-
ture for a period of 3 months (Nasreen et al., 2015).4. Conclusion
In this study, a drug delivery system of proliposome was pre-
pared with optimum conditions for oral administration by
the spray drying method. To obtain the highest entrapment
efﬁciency, the best composition was set as follows: concentra-
tion of GFS and EPC was 2 mg/ml; ratio of mannitol to EPC
was 12:5; ratio of NaDC to EPC was 23:100. The properties of
reconstituted liposomes including entrapment efﬁciency, parti-
cle size and zeta potential were characterized and optimized.
The results of FE-SEM visualization the formation and sur-
face morphology of reconstituted liposomes and. the molecu-
lar state of proliposomes, and some weak interaction
between the formulation ingredients, such as hydrogen bonds
or van der Waals forces were discussed according to the dia-
grams of DSC, and FT-IR. The in vitro drug release study indi-
cated that P-GFS has a controlled drug release proﬁle. A
further pharmacokinetic study suggested that proliposomes
increased the oral availability of GFS. The controlled release
and protection from the enzyme degradation of GRe and
sodium deoxycholate may signiﬁcantly decrease elimination
of GFS and enhance absorption in the gastrointestinal tract.
Moreover, the P-GFS had a good stability in the room temper-
ature. In summary, this study offers a new formulation proli-
posome, to improve the stability of oral administration drugs
that are subjected to degradation by the gastrointestinal
enzyme which led a short half-life in vivo. Proliposome could
be a potential formulation used for clinical application. How-
ever, further studies are needed to study the mechanism of the
improved bioavailability and two peaks of the P-GFS in the
plasma concentration–time proﬁles.
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